# SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Source: https://onco.cc/trials/nct06737081/  
OnCo record `nct06737081` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SAL-0951 tablets 4mg in advanced solid tumours, run by Shenzhen Salubris Pharmaceuticals Co., Ltd., now recruiting.

## Summary

SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies is a phase 2 interventional study registered as NCT06737081 by Shenzhen Salubris Pharmaceuticals Co., Ltd., with 60 participants planned, started 2024-09-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: SAL-0951 tablets 4mg and SAL-0951 tablets 5mg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06737081
- Phase: 2
- Setting: A Parallel, Open-label Phase II Clinical Study of Enarodustat (SAL-0951) Tablets in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
- Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06737081: https://clinicaltrials.gov/study/NCT06737081

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06737081.json